Annovis Bio, Inc. — Director's Dealing 2020

Jan 29, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Annovis Bio, Inc. (ANVS)
CIK: 0001477845
Period of Report: 2020-01-28

Reporting Person: Bruck Claudine (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Convertible Note	$		Common Stock ()		Direct
Series A-1 Preferred Stock	$		Common Stock (5556)		Direct
Stock Option (right to buy)	$0.14	2028-04-06	Common Stock (24997)		Direct
Stock Option (right to buy)	$0.25	2026-04-07	Common Stock (7142)		Direct

Footnotes

F1: The Convertible Notes have a maturity date of December 31, 2023. Prior to the maturity date, the Convertible Notes will automatically convert into common stock of Annovis Bio, Inc. ("Annovis") upon an initial public offering ("IPO") of Annovis at a conversion rate equal to the principal amount of the note, plus accrued and unpaid interest, divided by 80% of the public offering price per share of the IPO as set forth on the cover page of the final prospectus for the IPO.

F2: Each share of Series A-1 Preferred Stock is convertible into common stock of Annovis and has no expiration date. Upon the closing of the IPO, 7,778 shares of Series A-1 Preferred Stock, along with the aggregate accrued or accumulated and unpaid dividends thereon, will automatically be converted into 5,556 shares of common stock of the Issuer.

F3: As of the date of this report, all of the shares underlying the options are fully vested and exercisable.